America may face a public health crisis in coming years unless drastic changes are not made to the public perception of eye health, according to a report from the National Academies of Sciences, Engineering, and Medicine (NASEM). Taking steps to create a public conversation about the matter, Allergan has launched a public awareness campaign, See America, to improve this awareness of and access to comprehensive eye exams.
New treatments and greater awareness are making dry eye an even more important part of glaucoma care, according to Richard Lewis, MD, of Sacramento Eye Consultants.
Ophthalmologists are likely to continue grappling with changes brought about by the Medicare Access and CHIPS (Children’s Health Insurance Program) Reauthorization Act (MACRA) under the administration of President Donald J. Trump, according to Ruth D. Williams, MD.
Despite the legalization of marijuana by several state governments, physicians should not recommend smoking it as a treatment for glaucoma, said Sunita Radhakrishnan, MD. “It has been approved by public opinion rather than regulatory process,” said Sunita Radhakrishnan, MD.
Optical coherence tomography (OCT) is swiftly improving the diagnosis of glaucoma, according to Joel S. Schuman, MD, who helped invent the technology.
For his research efforts to better understand the molecular pathways that are responsible for axonal degeneration in glaucoma, Richard Libby, PhD, was awarded the 2017 Shaffer Prize for Research during Thursday night’s Glaucoma 360 annual Gala.
Over the years, Glaucoma 360 has brought the concept of innovation in glaucoma to the forefront. This year’s meeting will surpass the Glaucoma Research Foundation’s (GRF) own “Horizons” by adding a few more “degrees” to its 360-degree concept.
A renowned ophthalmologist and an accomplished opera singer were the highlight of Thursday night’s Glaucoma 360 annual Gala, when the two were presented with the Glaucoma Research Foundation’s (GRF) highest honors-The Catalyst Award and Visionary Award.
Since making the switch to a markerless toric alignment system, Bryan S. Lee, MD, JD, explains how the technology has eliminated ink marking from his surgical regimen.
Phenylephrine 1%/ketorolac injection 0.3% added to ophthalmic irrigation solution and administered intracamerally during cataract surgery was associated with a statistically significant reduction in surgical time, intraoperative complications, and use of pupil dilating devices and with a statistically significant improvement in best-corrected visual acuity.
A sophisticated integrated formula for IOL power prediction is the featured capability in upgrades to Clarity Medical Systems’ intraoperative wavefront aberrometer.
An intraoperative injection of a compounded formulation of triamcinolone acetonide, moxifloxacin, and vancomycin eliminated the need for supplemental postoperative medications in the vast majority of patients who underwent phacoemulsification and IOL implantation.
Having an awareness of current best practices-such as epidemiology, risk factors, signs and symptoms, and tests-can be key to identifying and treating corneal infections.
When his surgery center was in the market for a new phacoemulsification platform, medical director Jonathan Solomon, MD, decided to switch from a unit equipped with a flow-based peristaltic pump to technology that features a vacuum-based Venturi system (Stellaris PC, Bausch + Lomb).
Dr. David Chang, M.D. describes his experience with ZEISS Cataract Suite markerless.
I see the beginning of 2017 as fresh. A year of fresh possibilities. It is new and brimming with fresh beginnings, filled with hopes and dreams. If you are not feeling it, perhaps you are ensnared in the gray world of A, B, and C. This ABC is a continuous loop. You are not sure how you got there or how to get out.
Consider factors such as glaucoma severity, eye pigmentation, and medication use when selecting power settings for the MicroPulse P3 device.
Patients with cataract surgery and microstent implantation had a lowered IOP and a reduced number of medications used at 3 years postoperatively
Recent tooth loss and periodontal disease have been linked to primary open-angle glaucoma in a large prospective study of male health professionals.
Netarsudil ophthalmic solution 0.02% met its primary and secondary efficacy endpoints in a third phase III trial investigating its non-inferiority to timolol maleate 0.05% for IOP lowering.
A new add-on glaucoma module has the capability of creating an anatomic map of each patient’s eye by using two fixed landmarks. The module also includes an extensive reference data base.
New laser technology in a single device offers multiple treatment platforms, including SLT for glaucoma, laser vitreolysis for floaters, capsulotomy, and iridotomy.
Though much focus for stents has been in the trabecular meshwork, many companies are currently developing suprachorodial devices, which are in various stages of FDA review.
A new 0.075% formulation of bromfenac ophthalmic solution (BromSite, Sun Pharma) could provide relief from pain and inflammation associated with cataract surgery.
